Diabetic Retinopathy Market Research Report Information by Type (Non-proliferative and Proliferative), Treatment (Anti-VEGF Drugs, Laser Photocoagulation, Vitreoretinal Surgery, Steroid Injection), by End User (Hospitals, Ambulatory Surgical Centers, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032

Table Of Contents

REPORT PROLOGUE

MARKET INTRODUCTION

2.1. Definition

2.2. Scope Of The Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power Of Suppliers

5.1.2. Bargaining Power Of Buyers

5.1.3. Threat Of New Entrants

5.1.4. Threat Of Substitutes

5.1.5. Intensity Of Rivalry

5.2. Value Chain Analysis

GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE

6.1. Overview

6.2. Non-Proliferative

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

6.3. Proliferative

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT

7.1. Overview

7.2. Anti-VEGF Drugs

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

7.3. Laser Photocoagulation

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

7.4. Vitreoretinal Surgery

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

7.5. Steroid Injection

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER

8.1. Overview

8.2. Hospitals

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

8.3. Ambulatory Surgical Centers

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027

8.4. Others

Market Estimates & Forecast, By Region, 2020–2027

Market Estimates & Forecast, By Country, 2020–2027 9. GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest Of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest Of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

COMPANY PROFILES

11.1. F. Hoffmann-La Roche AG

11.1.1. Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Regeneron Pharmaceuticals, Inc.

11.2.1. Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Alimera Sciences

11.3.1. Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Ampio Pharmaceuticals Inc.

11.4.1. Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Aurolab

11.5.1. Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Allergan PLC

11.6.1. Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Abbott Laboratories

11.7.1. Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Others

APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL DIABETIC RETINOPATHY MARKET SYNOPSIS, 2020–2027

TABLE 2 GLOBAL DIABETIC RETINOPATHY MARKET ESTIMATES AND FORECAST, 2020–2027 (USD MILLION)

TABLE 3 GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 4 GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 5 GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 6 GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 7 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 9 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 10 US: DIABETIC RETINOPATHY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 11 US: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 12 US: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 13 CANADA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 14 CANADA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 15 CANADA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 16 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 17 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 18 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 19 EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 20 EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 21 EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR GLOBAL DIABETIC RETINOPATHY MARKET

FIGURE 3 MARKET DYNAMICS FOR GLOBAL DIABETIC RETINOPATHY MARKET

FIGURE 4 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 5 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 6 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)

FIGURE 13 GLOBAL DIABETIC RETINOPATHY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS

FIGURE 15 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE

FIGURE 16 F. HOFFMANN-LA ROCHE AG: GEOGRAPHICAL REVENUE

FIGURE 17 REGENERON PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 18 REGENERON PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 19 REGENERON PHARMACEUTICALS, INC.: GEOGRAPHICAL REVENUE

FIGURE 20 ALIMERA SCIENCES: KEY FINANCIALS

FIGURE 21 ALIMERA SCIENCES: SEGMENTAL REVENUE

FIGURE 22 ALIMERA SCIENCES: GEOGRAPHICAL REVENUE

FIGURE 23 AMPIO PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 24 AMPIO PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 25 AMPIO PHARMACEUTICALS INC.: GEOGRAPHICAL REVENUE

FIGURE 26 AUROLAB: KEY FINANCIALS

FIGURE 27 AUROLAB: SEGMENTAL REVENUE

FIGURE 28 AUROLAB: GEOGRAPHICAL REVENUE

FIGURE 29 ALLERGAN PLC: KEY FINANCIALS

FIGURE 30 ALLERGAN PLC: SEGMENTAL REVENUE

FIGURE 31 ALLERGAN PLC: GEOGRAPHICAL REVENUE

FIGURE 32 ABBOTT LABORATORIES: KEY FINANCIALS

FIGURE 33 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 34 ABBOTT LABORATORIES: GEOGRAPHICAL REVENUE